Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease
Open Access
- 1 December 1997
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 8 (12), 1243-1250
- https://doi.org/10.1023/a:1008238422151
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996
- Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorptionJournal of Bone and Mineral Research, 1994
- Evaluation of bone disease in breast cancerThe Breast, 1994
- Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myelomaBone, 1994
- ASSAY OF URINARY PYRIDINOLINE AND DEOXYPYRIDINOLINE AS POTENTIAL MARKERS OF THE RATE OF BONE RESORPTIONThe Japanese Journal of Urology, 1994
- Factors affecting the assay of urinary 3–hydroxy pyridiniurn crosslinks of collagen as markers of bone resorptionEuropean Journal of Clinical Investigation, 1993
- A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urineJournal of Bone and Mineral Research, 1992
- Randomised, placebo-controlled multicentre trial of clodronate in multiple myelomaThe Lancet, 1992
- A double-blind, crossover trial of intravenous clodronate in metastatic bone painJournal of Pain and Symptom Management, 1992